GOODRX REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS
Fourth Quarter and Full Year 2025 Revenue and Adjusted EBITDA Results In-line with Previous Guidance
Pharma Direct Revenue Beats Previous Outlook with Over 40% Year-Over-Year Growth for 2025
SANTA MONICA, Calif. -- (February 25, 2026) -- GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the
“Company”), the leading platform for medication savings in the U.S., has released its financial results for the fourth quarter
and full year of 2025.
Fourth Quarter 2025 Highlights
•Revenue of $194.8 million
•Net income of $5.4 million; Net income margin of 2.8%
•Adjusted Net Income1 of $29.0 million; Adjusted Net Income Margin1 of 14.9%
•Adjusted EBITDA1 of $65.0 million; Adjusted EBITDA Margin1 of 33.4%
•Net cash provided by operating activities of $32.9 million
Full Year 2025 Highlights
•Revenue of $796.9 million
•Net income of $30.4 million; Net income margin of 3.8%
•Adjusted Net Income1 of $126.1 million; Adjusted Net Income Margin1 of 15.8%
•Adjusted EBITDA1 of $270.5 million; Adjusted EBITDA Margin1 of 33.9%
•Net cash provided by operating activities of $167.9 million
“We delivered a strong finish to the year by executing across our key priorities, expanding manufacturer partnerships,
growing differentiated subscription offerings, and strengthening retail relationships,” said Wendy Barnes, President and Chief
Executive Officer of GoodRx. “We rebranded Pharma Manufacturer Solutions as Pharma Direct and are continuing to
elevate it as a key growth driver of our business, reflecting our belief that self-pay and direct-to-consumer engagement will
define the future of prescription access. We are confident that the actions we’re taking today position us to return to growth
beyond 2026, expand our role across the healthcare ecosystem, and create meaningful long-term value for consumers,
partners, and stockholders.”
1Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Net Income Margin are non-GAAP financial measures and are presented for
supplemental informational purposes only. Adjusted EBITDA Margin and Adjusted Net Income Margin are defined as Adjusted EBITDA and Adjusted Net
Income, respectively, divided by Adjusted Revenue. Refer to the Non-GAAP Financial Measures section below for definitions, additional information, and
reconciliations to the most directly comparable GAAP measures.
Full Year 2025 Financial Overview (all comparisons are made to the same period of the prior year unless otherwise
noted):
Revenue increased 1% to $796.9 million compared to $792.3 million.
Prescription transactions revenue decreased 6% to $544.0 million compared to $577.5 million, primarily driven by a decrease
in Monthly Active Consumers due to the broader changes in the retail pharmacy landscape, including store closures, and
volume reduction in one of our integrated savings programs, partially offset principally by improved unit economics related to
contracting with certain of our customers and partners and favorable changes in sales mix.
Subscription revenue decreased 3% to $83.8 million compared to $86.5 million, primarily driven by a decrease in the number
of our subscription plans.
Pharma direct (formerly pharma manufacturer solutions) revenue increased 41% to $151.4 million compared to $107.2
million, driven by organic growth as we continued to expand our market penetration with pharma manufacturers and other
customers, including ongoing growth in our consumer direct pricing.
Net income was $30.4 million compared to $16.4 million. Net income margin was 3.8% compared to 2.1%. Adjusted Net
Income1 was $126.1 million compared to $131.6 million.
Adjusted EBITDA1 was $270.5 million compared to $260.2 million. Adjusted EBITDA Margin1 was 33.9% compared to 32.8%.
Cash Flow and Capital Allocation
Net cash provided by operating activities in 2025 was $167.9 million compared to $183.9 million in 2024. As of December 31,
2025, we had cash and cash equivalents of $261.8 million and total outstanding debt of $495.0 million.
We are focused on a disciplined approach to capital allocation, centered on furthering our mission and creating stockholder
value. Our capital allocation priorities are investing for profitable growth, paying down debt, buying back shares, and M&A
that aligns with our strategic priorities. These capital allocation priorities support our long-term growth strategy while also
providing flexibility to navigate near-term challenges.
Share Repurchases
In 2025, we repurchased 48.9 million shares of Class A common stock for an aggregate cost of $217.4 million. As of
December 31, 2025, we had $72.9 million of unused authorized share repurchase capacity under our $450.0 million share
repurchase program, which does not have an expiration date.
Guidance
For the full year 2026, management is anticipating the following:
$ in millions | FY 2026 | FY 2025 | YoY Change |
Revenue | $750 - $780 | $796.9 | (6%) - (2%) |
Adjusted EBITDA2 | > $230 | ||
“We closed the year with disciplined financial performance and delivered results in line with our latest guidance,” said Chris
McGinnis, Chief Financial Officer and Treasurer of GoodRx. “Adjusted EBITDA finished just above the midpoint of our range,
reflecting continued cost discipline and focused execution across the business. Pharma Direct grew 41% year-over-year,
underscoring the strategic progress we are making as we reposition the Company. As we enter 2026, our priority is to
operate with rigor, preserve margin strength, and reinforce the long-term durability of our platform.”
2Adjusted EBITDA is a non-GAAP financial measure and is presented for supplemental informational purposes only. We have not reconciled our Adjusted
EBITDA guidance to GAAP net income or loss because we do not provide guidance for such GAAP measure due to the uncertainty and potential variability of
stock-based compensation expense, acquired intangible assets and related amortization and income taxes, which are reconciling items between Adjusted
EBITDA and the most directly comparable GAAP measure. Because such items cannot be provided without unreasonable efforts, we are unable to provide a
reconciliation of the non-GAAP financial measure guidance to the corresponding GAAP measure. However, such items could have a significant impact on our
future GAAP net income or loss.
Investor Conference Call and Webcast
GoodRx management will host a conference call and webcast tomorrow, February 26, 2026, at 5:00 a.m. Pacific Time (8:00
a.m. Eastern Time) to discuss the results and the Company’s business outlook.
To access the conference call, please pre-register using the following link:
https://register-conf.media-server.com/register/BIdac3339259784908974e81a19855a705
Registrants will receive a confirmation with dial-in details and a unique passcode required to join.
The call will also be webcast live on the Company’s investor relations website at https://investors.goodrx.com, where
accompanying materials will be posted prior to the conference call.
Approximately one hour after completion of the live call, an archived version of the webcast will be available on the
Company’s investor relations website at https://investors.goodrx.com for at least 30 days.
About GoodRx
GoodRx is the leading platform for medication savings in the U.S., used by nearly 25 million consumers and over one million
healthcare professionals annually. Uniquely situated at the center of the healthcare ecosystem, GoodRx connects
consumers, healthcare professionals, payers, pharmacy benefit managers, pharmaceutical manufacturers, and retail
pharmacies to make saving on medications easier. By reducing friction and inefficiencies, GoodRx helps consumers save
time and money when filling prescriptions so they can get the care they deserve. Since 2011, GoodRx has helped
Americans save over $100 billion on the cost of their medications.
GoodRx periodically posts information that may be important to investors on its investor relations website at https://
investors.goodrx.com. We intend to use our website as a means of disclosing material non-public information and for
complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are
encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press
releases, filings with the Securities and Exchange Commission and public conference calls and webcasts. The information
contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of,
this press release.
Investor Contact
GoodRx
Aubrey Reynolds
ir@goodrx.com
Press Contact
GoodRx
Lauren Casparis
lcasparis@goodrx.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements regarding our future results of operations and financial
position, industry and business trends, including uncertainty in the macro environment, the impact of trends impacting retail
pharmacies on our future financial results, the potential impact of the new government sponsored direct-to-consumer
platform called “TrumpRx.gov” and other evolving federal initiatives on our business, our value proposition, our business
strategy and our ability to execute on our strategic priorities including expanding manufacturer partnerships, growing
differentiated subscription offerings and strengthening retail relationships, our plans, market opportunity, ability to preserve
margin strength and long-term growth prospects, our capital allocation priorities, pharma direct as the future key growth
driver of our business, and the future of prescription access. These statements are neither promises nor guarantees, but
involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, risks related to our limited operating history and early stage of
growth; our recent growth rates may not be sustainable or indicative of future growth; our ability to achieve broad market
education and change consumer purchasing habits; our general ability to continue to attract, acquire and retain consumers
in a cost-effective manner; our significant reliance on our prescription transactions offering and ability to expand our
offerings; changes in medication pricing and the significant impact of pricing structures negotiated by industry participants;
our general inability to control the categories and types of prescriptions for which we can offer savings or discounted prices;
our reliance on a limited number of industry participants, including pharmacy benefit managers, pharmacies, and pharma
manufacturers; the competitive nature of our industry; risks related to pandemics, epidemics, or outbreak of infectious
disease; the accuracy of our estimate of our addressable market and other operational metrics; our ability to respond to
changes in the market for prescription pricing and to maintain and expand the use of GoodRx codes; our ability to maintain
positive perception of our platform or maintain and enhance our brand; risks related to any failure to maintain effective
internal control over financial reporting; risks related to use of social media, emails, text messages, and other messaging
channels as part of our marketing strategy; our dependence on our information technology systems and those of our third-
party vendors, and risks related to any failure or significant disruptions thereof; risks related to government regulation of the
internet, e-commerce, consumer data and privacy, information technology, and cybersecurity; risks related to the use of AI
and machine learning in our business; risks related to a decrease in consumer willingness to receive correspondence or any
technical, legal, or any other restrictions to send such correspondence; risks related to any failure to comply with applicable
data protection, privacy and security, advertising and consumer protection laws, regulations, standards, and other
requirements; our ability to utilize our net operating loss carryforwards and certain other tax attributes; the risk that we may
be unable to realize expected benefits from our restructuring and cost reduction efforts; our ability to attract, develop,
motivate and retain well-qualified employees; risks related to our acquisition strategy; risks related to our debt arrangements;
interruptions or delays in service on our apps or websites or any undetected errors or design faults; our reliance on third-
party platforms to distribute our platform and offerings, including software as-a-service technologies; systems failures or
other disruptions in the operations of these parties on which we depend; risks related to climate change; risks associated
with environmental sustainability and social initiatives; risks related to our intellectual property; risks related to operating in
the healthcare industry; risks related to our organizational structure; litigation related risks; our ability to accurately forecast
revenue and appropriately plan our expenses in the future; risks related to general economic factors, natural disasters, or
other unexpected events; risks related to fluctuations in our tax obligations and effective income tax rate which could
materially and adversely affect our results of operations; risks related to the healthcare reform legislation and other proposed
or future changes impacting the healthcare industry and healthcare spending, including the new platform TrumpRx, which
may adversely affect our business, financial condition and results of operations; as well as the other important factors
discussed in the section entitled “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31,
2025 and in our other filings with the Securities and Exchange Commission. The forward-looking statements in this press
release are based upon information available to us as of the date of this press release, and while we believe such
information forms a reasonable basis for such statements, such information may be limited or incomplete, and our
statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially
available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely
upon these statements. While we may elect to update such forward-looking statements at some point in the future, we
disclaim any obligation to do so, even if subsequent events cause our views to change.
Key Operating Metrics
Monthly Active Consumers (MACs) refers to the number of unique consumers who have used a GoodRx code to purchase a
prescription medication in a given calendar month and have saved money compared to the list price of the medication. A
unique consumer who uses a GoodRx code more than once in a calendar month to purchase prescription medications is
only counted as one Monthly Active Consumer in that month. A unique consumer who uses a GoodRx code in two or three
calendar months within a quarter will be counted as a Monthly Active Consumer in each such month. Monthly Active
Consumers do not include subscribers to our subscription offerings, consumers of our pharma direct offering, or consumers
who use our telehealth offering. When presented for a period longer than a month, Monthly Active Consumers are averaged
over the number of calendar months in such period. Monthly Active Consumers from acquired companies are only included
beginning in the first full quarter following the acquisition. Effective January 1, 2025, Monthly Active Consumers from
acquired companies are included beginning from the acquisition date. Prior to January 1, 2025, Monthly Active Consumers
from acquired companies were only included beginning in the first full quarter following the acquisition. As our business
continues to evolve, we are reassessing the Monthly Active Consumers metric as a primary indicator of performance to
ensure it aligns with how we measure growth and profitability.
Subscription plans represent the ending subscription plan balance across our subscription offerings, GoodRx Gold, Kroger
Savings Club (sunset in July 2024), condition-specific related subscription programs (first launched in June 2025), and
RxSmartSaver+ powered by GoodRx (launched in July 2025). For GoodRx Gold, Kroger Savings Club, and
RxSmartSaver+, each subscription plan may represent more than one subscriber since family subscription plans may
include multiple members.
Three Months Ended | |||||||||||||||
(in millions) | December 31, 2025 | September 30, 2025 | June 30, 2025 | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | |||||||
Monthly Active Consumers | 5.3 | 5.4 | 5.7 | 6.4 | 6.6 | 6.5 | 6.6 | 6.7 | |||||||
As of | |||||||||||||||
(in thousands) | December 31, 2025 | September 30, 2025 | June 30, 2025 | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | |||||||
Subscription plans | 674 | 671 | 668 | 680 | 684 | 701 | 696 | 778 | |||||||
GoodRx Holdings, Inc.
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except par values) | |||
December 31, 2025 | December 31, 2024 | ||
Assets | |||
Current assets | |||
Cash and cash equivalents | $261,820 | $448,346 | |
Accounts receivable, net | 235,746 | 145,934 | |
Prescription reimbursement assets | 98,331 | 22,944 | |
Prepaid expenses and other current assets | 47,205 | 42,031 | |
Total current assets | 643,102 | 659,255 | |
Property and equipment, net | 12,268 | 12,664 | |
Goodwill | 430,331 | 410,769 | |
Intangible assets, net | 64,082 | 52,102 | |
Capitalized software, net | 139,261 | 124,781 | |
Operating lease right-of-use assets, net | 28,808 | 27,794 | |
Deferred tax assets, net | 57,111 | 77,182 | |
Other assets | 29,095 | 23,520 | |
Total assets | $1,404,058 | $1,388,067 | |
Liabilities and stockholders' equity | |||
Current liabilities | |||
Accounts payable | $19,405 | $14,137 | |
Prescription reimbursement liabilities | 130,139 | 15,798 | |
Accrued expenses and other current liabilities | 86,705 | 83,332 | |
Current portion of debt | 5,000 | 5,000 | |
Operating lease liabilities, current | 4,753 | 5,636 | |
Total current liabilities | 246,002 | 123,903 | |
Debt, net | 483,264 | 486,711 | |
Operating lease liabilities, net of current portion | 49,789 | 46,040 | |
Other liabilities | 8,741 | 6,755 | |
Total liabilities | 787,796 | 663,409 | |
Stockholders' equity | |||
Preferred stock, $0.0001 par value | — | — | |
Common stock, $0.0001 par value | 34 | 38 | |
Additional paid-in capital | 2,026,802 | 2,165,633 | |
Accumulated deficit | (1,410,574) | (1,441,013) | |
Total stockholders' equity | 616,262 | 724,658 | |
Total liabilities and stockholders' equity | $1,404,058 | $1,388,067 | |
GoodRx Holdings, Inc.
Condensed Consolidated Statements of Operations (Unaudited)
(in thousands, except per share amounts) | |||||||
Three Months Ended December 31, | Year Ended December 31, | ||||||
2025 | 2024 | 2025 | 2024 | ||||
Revenue | $194,785 | $198,583 | $796,853 | $792,324 | |||
Costs and operating expenses: | |||||||
Cost of revenue, exclusive of depreciation and amortization presented separately below | 17,464 | 12,193 | 57,597 | 48,215 | |||
Product development and technology | 28,939 | 31,739 | 121,026 | 123,749 | |||
Sales and marketing | 78,616 | 93,829 | 331,560 | 367,114 | |||
General and administrative | 23,937 | 23,546 | 113,960 | 117,862 | |||
Depreciation and amortization | 23,146 | 19,096 | 85,218 | 69,538 | |||
Total costs and operating expenses | 172,102 | 180,403 | 709,361 | 726,478 | |||
Operating income | 22,683 | 18,180 | 87,492 | 65,846 | |||
Other expense, net: | |||||||
Other income (expense) | 24 | — | 718 | (2,660) | |||
Loss on extinguishment of debt | — | — | — | (2,077) | |||
Interest income | 1,889 | 4,587 | 10,933 | 23,273 | |||
Interest expense | (10,403) | (11,358) | (42,605) | (52,922) | |||
Total other expense, net | (8,490) | (6,771) | (30,954) | (34,386) | |||
Income before income taxes | 14,193 | 11,409 | 56,538 | 31,460 | |||
Income tax expense | (8,768) | (4,669) | (26,099) | (15,070) | |||
Net income | $5,425 | $6,740 | $30,439 | $16,390 | |||
Earnings per share: | |||||||
Basic | $0.02 | $0.02 | $0.09 | $0.04 | |||
Diluted | $0.02 | $0.02 | $0.09 | $0.04 | |||
Weighted average shares used in computing earnings per share: | |||||||
Basic | 340,205 | 381,607 | 356,327 | 385,737 | |||
Diluted | 340,761 | 383,576 | 356,973 | 392,172 | |||
Stock-based compensation included in costs and operating expenses: | |||||||
Cost of revenue | $49 | $94 | $357 | $320 | |||
Product development and technology | 5,504 | 6,158 | 22,547 | 24,649 | |||
Sales and marketing | 3,940 | 6,126 | 20,207 | 33,374 | |||
General and administrative | 8,426 | 8,581 | 33,515 | 40,683 | |||
GoodRx Holdings, Inc.
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands) | |||
Year Ended December 31, | |||
2025 | 2024 | ||
Cash flows from operating activities | |||
Net income | $30,439 | $16,390 | |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | 85,218 | 69,538 | |
Loss on extinguishment of debt | — | 2,077 | |
Amortization of debt issuance costs and discounts | 1,768 | 2,497 | |
Non-cash operating lease expense | 4,007 | 4,184 | |
Stock-based compensation expense | 76,626 | 99,026 | |
Deferred income taxes | 20,071 | (11,914) | |
Loss on operating lease assets | 4,409 | — | |
Other | 1,810 | — | |
Changes in operating assets and liabilities, net of effects of business acquisitions: | |||
Accounts receivable | (88,016) | (2,326) | |
Prescription reimbursement assets | (75,387) | (7,463) | |
Prepaid expenses and other assets | (8,387) | 13,790 | |
Accounts payable | 4,103 | (15,819) | |
Prescription reimbursement liabilities | 114,341 | 10,376 | |
Accrued expenses and other current liabilities | 1,185 | 9,911 | |
Operating lease liabilities | (6,269) | (4,953) | |
Other liabilities | 1,986 | (1,422) | |
Net cash provided by operating activities | 167,904 | 183,892 | |
Cash flows from investing activities | |||
Purchase of property and equipment | (3,521) | (1,240) | |
Acquisitions | (43,440) | — | |
Capitalized software | (70,499) | (69,107) | |
Other | (2,500) | — | |
Net cash used in investing activities | (119,960) | (70,347) | |
Cash flows from financing activities | |||
Proceeds from long-term debt | — | 472,033 | |
Payments on long-term debt | (5,000) | (639,038) | |
Payments of debt issuance costs | — | (2,673) | |
Repurchases of Class A common stock | (216,372) | (158,845) | |
Proceeds from exercise of stock options | 61 | 19,046 | |
Employee taxes paid related to net share settlement of equity awards | (14,467) | (29,784) | |
Proceeds from employee stock purchase plan | 1,308 | 1,766 | |
Net cash used in financing activities | (234,470) | (337,495) | |
Net change in cash and cash equivalents | (186,526) | (223,950) | |
Cash and cash equivalents | |||
Beginning of period | 448,346 | 672,296 | |
End of period | $261,820 | $448,346 | |
For the fourth quarters and full years of 2025 and 2024, revenue comprised of the following:
(in thousands) | |||||||
Three Months Ended December 31, | Year Ended December 31, | ||||||
2025 | 2024 | 2025 | 2024 | ||||
Prescription transactions revenue | $124,720 | $144,987 | $544,001 | $577,549 | |||
Subscription revenue | 21,582 | 20,676 | 83,786 | 86,536 | |||
Pharma direct revenue | 44,379 | 28,088 | 151,380 | 107,237 | |||
Other revenue | 4,104 | 4,832 | 17,686 | 21,002 | |||
Total revenue | $194,785 | $198,583 | $796,853 | $792,324 | |||
Reclassifications
Prior to December 31, 2025, prescription reimbursement assets were presented as a component of prepaid expenses and
other current assets, and prescription reimbursement liabilities as a component of accounts payable and accrued expenses
and other current liabilities on our condensed consolidated balance sheets. Amounts have been reclassified on the
condensed consolidated balance sheet as of December 31, 2024 to conform to the current period presentation.
Corresponding reclassifications were also reflected on the condensed consolidated statement of cash flows for the year
ended December 31, 2024. These reclassifications had no impact on previously reported current and total assets and
liabilities, total stockholders’ equity, results of operations, or cash flows provided by operating activities.
Non-GAAP Financial Measures
Adjusted Revenue and metrics presented as a percentage of Adjusted Revenue, Adjusted EBITDA, Adjusted EBITDA
Margin, Adjusted Net Income, Adjusted Net Income Margin, and Adjusted Earnings Per Share are supplemental measures of
our performance that are not required by, or presented in accordance with, U.S. GAAP. We also present each cost and
operating expense on our condensed consolidated statements of operations on an adjusted basis to arrive at adjusted
operating income. Collectively, we refer to these non-GAAP financial measures as our “Non-GAAP Measures."
We define Adjusted Revenue for a particular period as revenue excluding client contract termination costs associated with
restructuring related activities. We exclude these costs from revenue because we believe they are not indicative of past or
future underlying performance of the business. For 2025 and 2024, revenue equaled to Adjusted Revenue.
We define Adjusted EBITDA for a particular period as net income or loss before interest, taxes, depreciation and
amortization, and as further adjusted for, as applicable for the periods presented, acquisition related expenses, stock-based
compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt, financing
related expenses, loss on operating lease assets, restructuring related expenses, legal settlement expenses, gain on sale of
business, and other income or expense, net. Adjusted EBITDA Margin represents Adjusted EBITDA as a percentage of
Adjusted Revenue.
We define Adjusted Net Income for a particular period as net income or loss adjusted for, as applicable for the periods
presented, amortization of intangibles related to acquisitions and restructuring activities, acquisition related expenses, stock-
based compensation expense, payroll tax expense related to stock-based compensation, loss on extinguishment of debt,
financing related expenses, loss on operating lease assets, restructuring related expenses, legal settlement expenses, gain
on sale of business, other income or expense, net, and as further adjusted for estimated income tax on such adjusted items.
Our adjusted taxes also excludes (i) the valuation allowance recorded against certain of our net deferred tax assets that was
recognized in accordance with GAAP and any subsequent releases of the valuation allowance, and (ii) all tax benefits/
expenses resulting from excess tax benefits/deficiencies in connection with stock-based compensation. Adjusted Net
Income Margin represents Adjusted Net Income as a percentage of Adjusted Revenue.
Adjusted Earnings Per Share is Adjusted Net Income attributable to common stockholders divided by weighted average
number of shares. The weighted average shares we use in computing Adjusted Earnings Per Share – basic is equal to our
GAAP weighted average shares – basic and the weighted average shares we use in computing Adjusted Earnings Per
Share – diluted is equal to either GAAP weighted average shares – basic or GAAP weighted average shares – diluted,
depending on whether we have adjusted net loss or adjusted net income, respectively.
We also assess our performance by evaluating each cost and operating expense on our condensed consolidated
statements of operations on a non-GAAP, or adjusted, basis to arrive at adjusted operating income. The adjustments to
these cost and operating expense items include, as applicable for the periods presented, acquisition related expenses,
amortization of intangibles related to acquisitions and restructuring activities, stock-based compensation expense, payroll
tax expense related to stock-based compensation, financing related expenses, restructuring related expenses, legal
settlement expenses, loss on operating lease assets, and gain on sale of business. Adjusted operating income is Adjusted
Revenue less non-GAAP costs and operating expenses.
We believe our Non-GAAP Measures are helpful to investors, analysts and other interested parties because they assist in
providing a more consistent and comparable overview of our operations across our historical financial periods. Adjusted
Revenue, Adjusted EBITDA, and Adjusted EBITDA Margin are also key measures we use to assess our financial
performance and are also used for internal planning and forecasting purposes. In addition, Adjusted Revenue, Adjusted
EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Earnings Per Share are frequently used by analysts,
investors and other interested parties to evaluate and assess performance.
The Non-GAAP Measures are presented for supplemental informational purposes only and should not be considered as
alternatives or substitutes to financial information presented in accordance with GAAP. These measures have certain
limitations in that they do not include the impact of certain costs that are reflected in our condensed consolidated statements
of operations that are necessary to run our business. Other companies, including other companies in our industry, may not
use these measures or may calculate these measures differently than as presented herein, limiting their usefulness as
comparative measures.
The following table presents a reconciliation of net income (loss), the most directly comparable financial measure calculated in accordance with GAAP, to Adjusted
EBITDA, and presents net income (loss) margin, the most directly comparable financial measure calculated in accordance with GAAP, with Adjusted EBITDA Margin:
(dollars in thousands) | |||||||||||||||||||
Three Months Ended March 31, | Three Months Ended June 30, | Three Months Ended September 30, | Three Months Ended December 31, | Year Ended December 31, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | ||||||||||
Net income (loss) | $11,052 | $(1,009) | $12,843 | $6,694 | $1,119 | $3,965 | $5,425 | $6,740 | $30,439 | $16,390 | |||||||||
Adjusted to exclude the following: | |||||||||||||||||||
Interest income | (3,932) | (7,555) | (2,803) | (6,334) | (2,309) | (4,797) | (1,889) | (4,587) | (10,933) | (23,273) | |||||||||
Interest expense | 10,644 | 14,643 | 10,729 | 14,566 | 10,829 | 12,355 | 10,403 | 11,358 | 42,605 | 52,922 | |||||||||
Income tax expense | 5,616 | 1,302 | 6,734 | 4,952 | 4,981 | 4,147 | 8,768 | 4,669 | 26,099 | 15,070 | |||||||||
Depreciation and amortization | 20,912 | 15,942 | 19,729 | 16,965 | 21,431 | 17,535 | 23,146 | 19,096 | 85,218 | 69,538 | |||||||||
Other (income) expense | — | — | (694) | — | — | 2,660 | (24) | — | (718) | 2,660 | |||||||||
Loss on extinguishment of debt | — | — | — | — | — | 2,077 | — | — | — | 2,077 | |||||||||
Financing related expenses | — | 440 | — | 392 | — | 66 | — | — | — | 898 | |||||||||
Acquisition related expenses | 26 | 174 | — | 174 | 776 | 65 | 737 | 144 | 1,539 | 557 | |||||||||
Restructuring related expenses | 1,219 | (125) | 546 | 566 | 5,526 | — | 385 | 8,461 | 7,676 | 8,902 | |||||||||
Legal settlement expenses | — | 13,000 | 355 | — | 5,500 | — | — | — | 5,855 | 13,000 | |||||||||
Stock-based compensation expense | 19,174 | 25,096 | 21,415 | 26,590 | 18,118 | 26,381 | 17,919 | 20,959 | 76,626 | 99,026 | |||||||||
Payroll tax expense related to stock- based compensation | 685 | 879 | 549 | 847 | 313 | 510 | 150 | 235 | 1,697 | 2,471 | |||||||||
Loss on operating lease asset | 4,409 | — | — | — | — | — | — | — | 4,409 | — | |||||||||
Adjusted EBITDA | $69,805 | $62,787 | $69,403 | $65,412 | $66,284 | $64,964 | $65,020 | $67,075 | $270,512 | $260,238 | |||||||||
Revenue | $202,970 | $197,880 | $203,070 | $200,610 | $196,028 | $195,251 | $194,785 | $198,583 | $796,853 | $792,324 | |||||||||
Net income (loss) margin | 5.4% | (0.5%) | 6.3% | 3.3% | 0.6% | 2.0% | 2.8% | 3.4% | 3.8% | 2.1% | |||||||||
Adjusted EBITDA Margin | 34.4% | 31.7% | 34.2% | 32.6% | 33.8% | 33.3% | 33.4% | 33.8% | 33.9% | 32.8% | |||||||||
The following tables present a reconciliation of net income and calculations of net income margin and earnings per share,
the most directly comparable financial measures calculated in accordance with GAAP, to Adjusted Net Income, Adjusted Net
Income Margin, and Adjusted Earnings Per Share, respectively:
(dollars in thousands, except per share amounts) | |||||||
Three Months Ended December 31, | Year Ended December 31, | ||||||
2025 | 2024 | 2025 | 2024 | ||||
Net income | $5,425 | $6,740 | $30,439 | $16,390 | |||
Adjusted to exclude the following: | |||||||
Amortization of intangibles related to acquisitions and restructuring related activities | 3,541 | 2,946 | 11,920 | 9,783 | |||
Other (income) expense | (24) | — | (718) | 2,660 | |||
Loss on extinguishment of debt | — | — | — | 2,077 | |||
Financing related expenses | — | — | — | 898 | |||
Acquisition related expenses | 737 | 144 | 1,539 | 557 | |||
Restructuring related expenses | 385 | 8,461 | 7,676 | 8,902 | |||
Legal settlement expenses | — | — | 5,855 | 13,000 | |||
Stock-based compensation expense | 17,919 | 20,959 | 76,626 | 99,026 | |||
Payroll tax expense related to stock-based compensation | 150 | 235 | 1,697 | 2,471 | |||
Loss on operating lease asset | — | — | 4,409 | — | |||
Income tax effects of excluded items and adjustments for valuation allowance and excess tax benefits/deficiencies from equity awards | 866 | (4,737) | (13,357) | (24,122) | |||
Adjusted Net Income | $28,999 | $34,748 | $126,086 | $131,642 | |||
Revenue | $194,785 | $198,583 | $796,853 | $792,324 | |||
Net income margin | 2.8% | 3.4% | 3.8% | 2.1% | |||
Adjusted Net Income Margin | 14.9% | 17.5% | 15.8% | 16.6% | |||
Weighted average shares used in computing earnings per share: | |||||||
Basic | 340,205 | 381,607 | 356,327 | 385,737 | |||
Diluted | 340,761 | 383,576 | 356,973 | 392,172 | |||
Earnings per share: | |||||||
Basic | $0.02 | $0.02 | $0.09 | $0.04 | |||
Diluted | $0.02 | $0.02 | $0.09 | $0.04 | |||
Weighted average shares used in computing Adjusted Earnings Per Share: | |||||||
Basic | 340,205 | 381,607 | 356,327 | 385,737 | |||
Diluted | 340,761 | 383,576 | 356,973 | 392,172 | |||
Adjusted Earnings Per Share: | |||||||
Basic | $0.09 | $0.09 | $0.35 | $0.34 | |||
Diluted | $0.09 | $0.09 | $0.35 | $0.34 | |||
The following table presents (i) each non-GAAP, or adjusted, cost and expense and operating income measure together with
its most directly comparable financial measure calculated in accordance with GAAP; and (ii) each adjusted cost and
expense and adjusted operating income as a percentage of Adjusted Revenue together with each GAAP cost and expense
and operating income as a percentage of revenue, the most directly comparable financial measure calculated in accordance
with GAAP:
(dollars in thousands) | |||||||||||||||
GAAP | Adjusted | GAAP | Adjusted | ||||||||||||
Three Months Ended December 31, | Three Months Ended December 31, | Year Ended December 31, | Year Ended December 31, | ||||||||||||
2025 | 2024 | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | ||||||||
Cost of revenue | $17,464 | $12,193 | $17,400 | $12,071 | $57,597 | $48,215 | $57,132 | $48,164 | |||||||
% of Revenue | 9% | 6% | 9% | 6% | 7% | 6% | 7% | 6% | |||||||
Product development and technology | $28,939 | $31,739 | $23,294 | $24,318 | $121,026 | $123,749 | $93,801 | $96,528 | |||||||
% of Revenue | 15% | 16% | 12% | 12% | 15% | 16% | 12% | 12% | |||||||
Sales and marketing | $78,616 | $93,829 | $74,120 | $80,651 | $331,560 | $367,114 | $307,550 | $325,760 | |||||||
% of Revenue | 40% | 47% | 38% | 41% | 42% | 46% | 39% | 41% | |||||||
General and administrative | $23,937 | $23,546 | $14,951 | $14,468 | $113,960 | $117,862 | $67,858 | $61,634 | |||||||
% of Revenue | 12% | 12% | 8% | 7% | 14% | 15% | 9% | 8% | |||||||
Depreciation and amortization | $23,146 | $19,096 | $19,605 | $16,150 | $85,218 | $69,538 | $73,298 | $59,755 | |||||||
% of Revenue | 12% | 10% | 10% | 8% | 11% | 9% | 9% | 8% | |||||||
Operating income | $22,683 | $18,180 | $45,415 | $50,925 | $87,492 | $65,846 | $197,214 | $200,483 | |||||||
% of Revenue | 12% | 9% | 23% | 26% | 11% | 8% | 25% | 25% | |||||||
The following table presents a reconciliation of each non-GAAP, or adjusted, cost and expense and operating income
measure to its most directly comparable financial measure calculated in accordance with GAAP:
(dollars in thousands) | |||||||
Three Months Ended December 31, | Year Ended December 31, | ||||||
2025 | 2024 | 2025 | 2024 | ||||
Cost of revenue | $17,464 | $12,193 | $57,597 | $48,215 | |||
Acquisition related expenses | (14) | — | (14) | — | |||
Restructuring related expenses | — | (27) | (80) | 284 | |||
Stock-based compensation expense | (49) | (94) | (357) | (320) | |||
Payroll tax expense related to stock-based compensation | (1) | (1) | (14) | (15) | |||
Adjusted cost of revenue | $17,400 | $12,071 | $57,132 | $48,164 | |||
Product development and technology | $28,939 | $31,739 | $121,026 | $123,749 | |||
Acquisition related expenses | (68) | — | (68) | (62) | |||
Restructuring related expenses | — | (1,163) | (3,689) | (1,275) | |||
Stock-based compensation expense | (5,504) | (6,158) | (22,547) | (24,649) | |||
Payroll tax expense related to stock-based compensation | (73) | (100) | (921) | (1,235) | |||
Adjusted product development and technology | $23,294 | $24,318 | $93,801 | $96,528 | |||
Sales and marketing | $78,616 | $93,829 | $331,560 | $367,114 | |||
Acquisition related expenses | (139) | — | (139) | (351) | |||
Restructuring related expenses | (379) | (6,988) | (3,249) | (7,102) | |||
Stock-based compensation expense | (3,940) | (6,126) | (20,207) | (33,374) | |||
Payroll tax expense related to stock-based compensation | (38) | (64) | (415) | (527) | |||
Adjusted sales and marketing | $74,120 | $80,651 | $307,550 | $325,760 | |||
General and administrative | $23,937 | $23,546 | $113,960 | $117,862 | |||
Financing related expenses | — | — | — | (898) | |||
Acquisition related expenses | (516) | (144) | (1,318) | (144) | |||
Restructuring related expenses | (6) | (283) | (658) | (809) | |||
Legal settlement expenses | — | — | (5,855) | (13,000) | |||
Stock-based compensation expense | (8,426) | (8,581) | (33,515) | (40,683) | |||
Payroll tax expense related to stock-based compensation | (38) | (70) | (347) | (694) | |||
Loss on operating lease asset | — | — | (4,409) | — | |||
Adjusted general and administrative | $14,951 | $14,468 | $67,858 | $61,634 | |||
Depreciation and amortization | $23,146 | $19,096 | $85,218 | $69,538 | |||
Amortization of intangibles related to acquisitions and restructuring related activities | (3,541) | (2,946) | (11,920) | (9,783) | |||
Adjusted depreciation and amortization | $19,605 | $16,150 | $73,298 | $59,755 | |||
Operating income | $22,683 | $18,180 | $87,492 | $65,846 | |||
Amortization of intangibles related to acquisitions and restructuring related activities | 3,541 | 2,946 | 11,920 | 9,783 | |||
Financing related expenses | — | — | — | 898 | |||
Acquisition related expenses | 737 | 144 | 1,539 | 557 | |||
Restructuring related expenses | 385 | 8,461 | 7,676 | 8,902 | |||
Legal settlement expenses | — | — | 5,855 | 13,000 | |||
Stock-based compensation expense | 17,919 | 20,959 | 76,626 | 99,026 | |||
Payroll tax expense related to stock-based compensation | 150 | 235 | 1,697 | 2,471 | |||
Loss on operating lease asset | — | — | 4,409 | — | |||
Adjusted operating income | $45,415 | $50,925 | $197,214 | $200,483 | |||